Scott Kizy1, Cyrus Jahansouz1, Michael C Downey2, Nathanael Hevelone3, Sayeed Ikramuddin1, Daniel Leslie4. 1. Department of Surgery, University of Minnesota, 420 Delaware St. SE, Minneapolis, MN, 55455, USA. 2. Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, 55455, USA. 3. Department of Healthcare Outcomes, Covidien and Medtronic, Boston, MA, 02048, USA. 4. Department of Surgery, University of Minnesota, 420 Delaware St. SE, Minneapolis, MN, 55455, USA. Lesli002@umn.edu.
Abstract
BACKGROUND: Bariatric surgery is widely accepted as the best treatment for obesity and type 2 diabetes mellitus (T2DM). The Roux-en-Y gastric bypass (RYGB) and the sleeve gastrectomy (SG) have become the predominant bariatric procedures in the USA over the last several years, although the most recent trends in selection are unknown. OBJECTIVE: The objective of this study is to assess selection trends, readmission rates, and cost of bariatric procedures in the USA from 2012 to 2015. METHODS: We used the Premier database from 2012 to 2015 to examine trends in incidence of RYGB, adjustable gastric banding (LAGB), and SG; readmissions; and cost. Multivariate regression was performed to identify predictors of readmission. RESULTS: The proportion of SG went up from 38 to 63% while the RYGB decreased from 44 to 30% over this time period. LAGB has decreased in use from 13 to 2%. In comparison to RYGB, readmission was less likely for SG (OR 0.64), males (OR 0.91), and more likely for black race (OR 1.27). The overall proportion of patients seeking RYGB with type 2 diabetes was higher than with SG (36 versus 25%), but SG has now overtaken RYGB as the most common procedure among diabetics. The SG is less costly than RYGB ($11,183 versus $13,485). CONCLUSIONS: There is a continued overall trend in the increased popularity of the SG and decreased utilization of the RYGB and LAGB, although growth of the SG appears to be slowing. This is also true among patients with type 2 diabetes mellitus. Regardless of surgery type, underinsured and African-American race were more likely to be readmitted.
BACKGROUND: Bariatric surgery is widely accepted as the best treatment for obesity and type 2 diabetes mellitus (T2DM). The Roux-en-Y gastric bypass (RYGB) and the sleeve gastrectomy (SG) have become the predominant bariatric procedures in the USA over the last several years, although the most recent trends in selection are unknown. OBJECTIVE: The objective of this study is to assess selection trends, readmission rates, and cost of bariatric procedures in the USA from 2012 to 2015. METHODS: We used the Premier database from 2012 to 2015 to examine trends in incidence of RYGB, adjustable gastric banding (LAGB), and SG; readmissions; and cost. Multivariate regression was performed to identify predictors of readmission. RESULTS: The proportion of SG went up from 38 to 63% while the RYGB decreased from 44 to 30% over this time period. LAGB has decreased in use from 13 to 2%. In comparison to RYGB, readmission was less likely for SG (OR 0.64), males (OR 0.91), and more likely for black race (OR 1.27). The overall proportion of patients seeking RYGB with type 2 diabetes was higher than with SG (36 versus 25%), but SG has now overtaken RYGB as the most common procedure among diabetics. The SG is less costly than RYGB ($11,183 versus $13,485). CONCLUSIONS: There is a continued overall trend in the increased popularity of the SG and decreased utilization of the RYGB and LAGB, although growth of the SG appears to be slowing. This is also true among patients with type 2 diabetes mellitus. Regardless of surgery type, underinsured and African-American race were more likely to be readmitted.
Authors: Ali Aminian; Stacy A Brethauer; Amin Andalib; Suriya Punchai; Jennifer Mackey; John Rodriguez; Tomasz Rogula; Matthew Kroh; Philip R Schauer Journal: Ann Surg Date: 2016-10 Impact factor: 12.969
Authors: Stacy A Brethauer; Ali Aminian; Héctor Romero-Talamás; Esam Batayyah; Jennifer Mackey; Laurence Kennedy; Sangeeta R Kashyap; John P Kirwan; Tomasz Rogula; Matthew Kroh; Bipan Chand; Philip R Schauer Journal: Ann Surg Date: 2013-10 Impact factor: 12.969
Authors: Ninh T Nguyen; Jeffrey Root; Kambiz Zainabadi; Allen Sabio; Sara Chalifoux; C Melinda Stevens; Shahrzad Mavandadi; Mario Longoria; Samuel E Wilson Journal: Arch Surg Date: 2005-12
Authors: Jonathan P Weiner; Suzanne M Goodwin; Hsien-Yen Chang; Shari D Bolen; Thomas M Richards; Roger A Johns; Soyal R Momin; Jeanne M Clark Journal: JAMA Surg Date: 2013-06 Impact factor: 14.766
Authors: Corey J Lager; Nazanene H Esfandiari; Angela R Subauste; Andrew T Kraftson; Morton B Brown; Ruth B Cassidy; Catherine K Nay; Amy L Lockwood; Oliver A Varban; Elif A Oral Journal: Obes Surg Date: 2017-01 Impact factor: 4.129
Authors: Ivy N Haskins; Tammy Ju; Ashlyn E Whitlock; Lisbi Rivas; Richard L Amdur; Paul P Lin; Khashayar Vaziri Journal: Obes Surg Date: 2018-09 Impact factor: 4.129
Authors: Colette S Inaba; Christina Y Koh; Sarath Sujatha-Bhaskar; Jack P Silva; Yanjun Chen; Danh V Nguyen; Ninh T Nguyen Journal: J Am Coll Surg Date: 2018-03-16 Impact factor: 6.113
Authors: S De Carolis; A Botta; Gelsomina Del Sordo; R Guerrisi; S Salvi; M P De Carolis; A Iaconelli; P Giustacchini; M Raffaelli; A Lanzone Journal: Obes Surg Date: 2018-10 Impact factor: 4.129
Authors: Russell D Dolan; Jason Baker; Kimberly Harer; Allen Lee; William Hasler; Richard Saad; Allison R Schulman Journal: Obes Surg Date: 2020-10-12 Impact factor: 4.129